04:45 PM EDT, 03/19/2026 (MT Newswires) -- SAB Biotherapeutics ( SABS ) said Thursday it has completed an underwritten public offering of roughly 19.3 million common shares at $3.85 per share, alongside pre-funded warrants to buy about 2.8 million shares at $3.8499 each for certain investors.

The gross proceeds from the transaction amounted to roughly $85 million, while the underwriters have received a 30-day option to purchase up to an additional 3.3 million shares, the company said.

Net proceeds will be utilized to finance the ongoing development of the SAB-142 clinical-stage product candidate, as well as for manufacturing, working capital, and general corporate activities, SAB Biotherapeutics ( SABS ) said.